Study #2023-0634
A phase 1 study investigating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of HPK1 inhibitor BGB-26808 alone or in combination with ANTI-PD-1 monoclonal antibody Tislelizumab in patients with advanced solid tumors.
MD Anderson Study Status
Enrolling
Treatment Agent
BGB-26808, Tislelizumab, Chemotherapy
Description
This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-26808.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Solid Tumor, Solid Tumor
Study phase:
Phase I
Physician name:
Aung Naing
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-877-563-0193
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.